|Last Price$1.72||Day Change (%)5.52%|
|Open Price$1.63||Day Change ($)0.09|
|Day Range1.61–1.73||52-Week Range1.26–7.64|
As of Mon 01/26/2015 07:52 PM EST | USD
The lack of early success in its lead drug's cancer trial scares the market, but we see a buying opportunity.
Lack of competitive advantages may mean these companies aren't the bargains they seem to be.
We see opportunity as fleeing investors trigger an irrational sell-off.
Morningstar analysts see pharmaceuticals as 2010's hot zone for mergers and acquisitions.
The five biotech ETFs have very different portfolios with markedly different performance.